Parkinson's Disease Clinical Trial
— PDAE in PDOfficial title:
Partnered Dance Aerobic Exercise as a Neuroprotective, Motor and Cognitive Intervention in Parkinson's Disease
Parkinson's disease (PD) is a difficult to treat condition that impairs mobility and thinking. It is not fully treated by drugs and surgery. Two priority issues for most people with PD are "OFF-time" and Cognitive impairment. Even under best medical management, 74% of people with PD experience "OFF-time," which is when medications are just not working right. OFF-time severely impacts both quality of life and thinking. Cognitive problems are found even in newly diagnosed people with PD and are very difficult to treat. However, the investigators' research has shown that partnered dance-aerobic exercise (PDAE) reduces OFF-time on the official test for OFF-time of the Movement Disorders Society, the Movement Disorders Society Unified Parkinson Disease Rating Scale-IV, (MDS-UPDRS-IV). PDAE improves other symptoms too. Benefits of the therapy have lasted for at least one-month after PDAE sessions stopped. PDAE provides aerobic exercise during an improvisational, cognitively-engaging physical activity. Cognitive engagement is a critical component of PDAE. Previous research showed PDAE improved spatial cognition, the ability to navigate, to mentally picture shapes and paths in the mind and to know the relationships between objects, people and places. Also, the investigators showed with imaging of the brain using a magnet in a scanner that twice weekly PDAE training increases activity in brain regions used in thinking and decision making. The investigators know that exercise benefits mobility and cognitive problems. The investigators even think exercise might protect brain cells in people with PD. But no one has really been able to show with biomarkers that exercise is protective of brain cells in humans.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | October 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 89 Years |
Eligibility | Inclusion Criteria: - Age: older than 40 years (40 is upper limit for young onset PD) - Montreal Cognitive Assessment (MoCA) score >17 - Able to walk with or without an assistive device at least 10 feet - Best corrected/aided acuity better than 20/70 in the better eye - Willingness to be randomized to either group - H&Y stages I-III - Report OFF times (reporting >0 on item 4.3 of the UPDRS-IV) - Show clear symptomatic benefit from antiparkinsonian medications - e.g., alleviated rigidity, bradykinesia, and tremor - Fluent in English to comprehend and participate Exclusion Criteria: - Untreated Major Depression and major psychiatric illness - History of stroke, or traumatic brain injury - Pure-tone threshold average sensitivity at 0.5, 1.0, and 2.0 kHz exceeds 40 dB - Previous participation in PDAE or WAE classes. - Alcohol abuse and/or use of antipsychotics - Lives outside of the study site or is planning to move out of the area in next year or leave the area for >1 month during the next year - Taking moderate to high doses of beta-blockers with a resting heart rate below 60 beats/min since exercise intensity is measured through target heart rate. - Severe cardiac disease, including: - New York Heart Association (NYHA) Class III or IV congestive heart failure - clinically significant aortic stenosis - history of cardiac arrest, use of a cardiac defibrillator - uncontrolled angina - as discussed we are not planning to perform routine exercise tolerance tests prior to enrollment - Other significant co-morbid disease that would impair ability to participate in the exercise-based intervention - e.g. renal failure on hemodialysis, excessive alcohol use (>14 drinks per wk) - Any contraindications to MRI eg claustrophobia, etc |
Country | Name | City | State |
---|---|---|---|
United States | Atlanta VA Medical and Rehab Center, Decatur, GA | Decatur | Georgia |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mini BESTest score | The Mini BESTest is a 14-item test scored on a 3-level ordinal scale. Mini BESTest assesses dynamic balance, a unidimensional construct. It is validated in PD. | 16 months | |
Other | Four Square Step Test (time to complete) | The FSST is a valid measure of motor cognitive integration and involves the participant stepping as quickly and safely as they can in four quadrants created by four canes arranged in a cross, in a clockwise order and then switching to counterclockwise order. | 16 months | |
Other | Dynamic Gait index | The DGI is a clinical tool to assess gait, balance and fall risk. It evaluates not only usual steady-state walking, but also walking during more challenging tasks. | 16 months | |
Other | Single/Dual Timed up and go (time to complete and dual task costs) | Timed Up & Go Test (TUG) is a test of balance that is commonly used to examine functional mobility. The single condition requires participants to get up from a chair walk three meters, turn around and return to the chair as quickly and as safely as they can. The dual versions involve cognitive tasks (counting backward by 3s from given number) and manual, holding a full cup of water, while performing single tug. | 16 months | |
Other | Parkinson Disease Questionnaire -39 | The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month Assesses how often patients experience difficulties across the 8 quality of life dimensions | 16 months | |
Other | composite physical function index | This validate scale assesses the ability of people with impairments to complete various tasks of daily living ranging from holding a bag of groceries to walking a couple of blocks to being able to take a bath unassisted. | 16 months | |
Other | Movement disorders Society Unified Parkinson's disease rating scale parts I-III | Part I assesses non motor aspects of experiences of daily living for people with PD. Part II assesses motor aspects of experiences of daily living for people with PD. Part III is a rated scale of motor function. The MDS UPDRS is validated and reliable and widely used globally. | 16 months | |
Other | Beck depression inventory score | This widely used test of depression is validated in PD. | 16 months | |
Other | Freezing of Gait questionnaire total score | The Freezing of Gait Questionnaire (FOG-Q) reliably detects FOG in patients with Parkinson's disease (PD). | 16 months | |
Other | Physical Scale for the Elderly score (PASE) | PASE comprises measures of self-reported occupational, household, and leisure activities during a one-week period. Designed for use in epidemiologic studies and exercise interventions, the instrument can be administered by telephone, mail, or in person in 5 to 15 minutes. | 16 months | |
Other | Short Form 12 | A generic, multipurpose short-form survey with 12 questions selected from the SF-36 Health Survey which, when combined, scored and weighted, results in two scales of mental and physical functioning and overall health-related quality of life. Subscales of interest include the Mental composite and physical composite scores among others. | 16 months | |
Other | Satisfaction with Training period questionnaire | Participants will complete the Exit Questionnaire which asks their level of agreement on a Likert scale (1-5) with 1 indicating the most agreement about whether they think they improved in various aspects of wellbeing. | 3 months | |
Other | Satisfaction with Maintenance period questionnaire | Participants will complete the Exit Questionnaire which asks their level of agreement on a Likert scale (1-5) with 1 indicating the most agreement about whether they think they improved in various aspects of wellbeing. | 16 months | |
Other | Satisfaction with Life scale | Valid for PD, this scale allows self report of level of satisfaction with life and life events in people with PD. | 16 months | |
Other | Multidimensional Scale of Perceived social support (MSPSS) | The MSPSS aims to determine how social support factors are perceived by individuals, with three subscales to evaluate support by family, friends and significant others. | 16 months | |
Primary | Movement disorders Society Unified Parkinson's Disease Rating Scale Part IV total score | The primary outcome, the MDS-UPDRS-IV score measures medication related motor fluctuations, including dyskinesias, OFF-time, functional impact and complexity of fluctuations, and dystonia. The investigators will administer a monthly OFF-state diary for corroboration of these scores. | 16 months | |
Primary | Corsi Blocks product score | The product score is the product of the span and number of correct trials achieved by the participant. The Corsi Blocks is a test of spatial cognition, specifically visuospatial working memory. | 16 months | |
Primary | rate of change in iron accumulation in the substantia nigra pars compacta | The investigators will measure R2* in the NM-MRI defined SNc using a published image processing and analysis method. This method leverages a standard space SNc atlas developed using control population NM-MRI data, enabling R2* measurement in SNc with no operator-dependent segmentation steps | 16 months | |
Secondary | 6 minute walk test (number of meters walked in 6 minutes) | The six minute walk test is a validated test of endurance in older adults and in those with Parkinson disease. Participants are asked to walk as far as they can in 6 minutes, while being monitored and able to carry on a conversation. The distance is measured in meters. | 16 months | |
Secondary | cardiovascular output: V02 maximum | This sub-maximal test can estimate the participant's VO2max and initial fitness level. This test uses a method in which heart rate (HR) workload values are obtained at 2-4 points and extrapolated to predict workload at the estimated maximum HR (e.g. 220-age). VO2max is then calculated from the predicted maximum workload. | 16 months | |
Secondary | neural measure of spatial cognition (BOLD signal) | At each study visit T1 MPRAGE, and T2* weighted blood oxygen level dependent (BOLD) fMRI data will be acquired at the Emory CSI, using a Siemens Prisma-Fit 3T MRI scanner with a 64 channel receive-only head coil in a protocol with total scan time one hour. BOLD signal will be measured in response to the functional task, the Block span task. | 16 months | |
Secondary | rate of change in loss of neuromelanin in substantia nigra pars compacta | At each study visit NM-MRI, R2*, T1 MPRAGE, and T2* weighted blood oxygen level dependent (BOLD) fMRI data will be acquired. The investigators will carry out image processing to determine SNc volume using an automated approach previously shown to have high scan-rescan reproducibility. | 16 months | |
Secondary | Executive function: Tower Of London achievement score | The Delis Kaplan tower of London test is a validated measure of executive function in PD. | 16 months | |
Secondary | Benton's judgment of line orientation task | Judgment of Line Orientation is a standardized test of visuospatial skills commonly associated with functioning of the parietal lobe in the right hemisphere. The test measures a person's ability to match the angle and orientation of lines in space. Subjects are asked to match two angled lines to a set of 11 lines that are arranged in a semicircle and separated 18 degrees from each other. | 16 months | |
Secondary | gait- forward, fast as possible, backward speeds | Objective, spatiotemporal parameters including velocity, stride length, stance percent, velocity variability and other variables of preferred, backward and fast-as-possible walking will be assessed. | 16 months | |
Secondary | attention: Trails Making Test A | Trails making test A is a validated measure of attention and visuospatial processing in people with PD. The time to complete is considered. | 16 months | |
Secondary | spatial imagery: Brooks spatial memory task percent correct | Brooks spatial memory involves reporting back a specified path of numbers that patients are asked to visualize in a 4 x 4 grid. | 16 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A | |
Completed |
NCT02939391 -
A Study of KW-6356 in Subjects With Early Parkinson's Disease
|
Phase 2 |